Truist Securities Reiterates Buy on Regeneron Pharmaceuticals, Maintains $1200 Price Target
Portfolio Pulse from Benzinga Newsdesk
Truist Securities has reiterated its Buy rating for Regeneron Pharmaceuticals, maintaining a price target of $1200.
September 24, 2024 | 1:49 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Truist Securities has reiterated its Buy rating for Regeneron Pharmaceuticals, maintaining a price target of $1200. This suggests confidence in the company's future performance.
The reiteration of a Buy rating and a high price target by Truist Securities indicates positive sentiment and confidence in Regeneron's future performance, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100